Hyperbaric oxygen therapy for Alzheimer’s dementia with positron emission tomography imaging

The prevalence and costs of dementia, of which Alzheimer’s dementia (AD) is the dominant subtype, are substantial. AD is characterized by deficits in memory and executive function. Treatments have focused on pharmacotherapy, but from 2002–2012 the US Food and Drug Administration has cleared only 1 of 244 drugs tested6 and no therapy halts disease progression.